Strategic Alliances in World Pharma and Biotech Markets
Every pharma or biotech company has certain limitations in their own research although usually they have enough capacity in development to bring new compounds to the market very effectively. However, on a number of occasions, the in-house development capacity may get prioritized in favor of other products within the company’s portfolio. A product may also be facing competition internally from other projects, not necessarily similar compounds, but perhaps programs better aligned to the overall R&D activities. All these make collaboration a viable option, not only to enhance company’s product range, but also its geographic coverage.
Recent statistics indicate that all the big pharmaceutical and biotechnology companies have in fact become quite dependent on products derived from collaborations and the on an average, 15%-20% of the sales revenue of top 20 companies comes from licensed products, while around 40% of their pipelines is due to compounds externally sourced.
Other Topics covered in this report include: Introduction to the Synergy between Pharma and Biotech Industries; Introduction to the Biotechnology Industry and Drug Development;
.
About the Publisher: "Strategic Alliances in World Pharma and Biotech Markets " is published by Pharma-Reports (www.Pharma-
Photo:
http://www.prlog.org/
